Ascendis Pharma A/S

NasdaqGS ASND

Ascendis Pharma A/S Price to Earnings Ratio (P/E) on December 30, 2024: -17.54

Ascendis Pharma A/S Price to Earnings Ratio (P/E) is -17.54 on December 30, 2024, a -15.28% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Ascendis Pharma A/S 52-week high Price to Earnings Ratio (P/E) is -12.82 on September 11, 2024, which is 26.90% above the current Price to Earnings Ratio (P/E).
Ascendis Pharma A/S 52-week low Price to Earnings Ratio (P/E) is -19.18 on September 30, 2024, which is -9.33% below the current Price to Earnings Ratio (P/E).
Ascendis Pharma A/S average Price to Earnings Ratio (P/E) for the last 52 weeks is -15.86.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqGS: ASND

Ascendis Pharma A/S

CEO	Mr. Jan Moller Mikkelsen
IPO Date	Jan. 28, 2015
Location	Denmark
Headquarters	Tuborg Boulevard 12
Employees	879
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Key trends

Past 5 years